Canadian Cannabis LPs: CGC's Plunge Drags Category Down

Of the 950 companies that are licensed by Health Canada to cultivate, process and sell cannabis for medical or non-medical purposes (see here) only 5 have market capitalizations of at least $300M; those are the ones we track in our Canadian Cannabis LPs Index .

This article highlights the week's performance of each of those 5 constituents, in descending order, and YTD, with links to summary articles on each of their latest quarter financial results and a link to a recent article which highlights the financial health of each constituent.

1. OrganiGram (OGI): DOWN 7.7% this week; UP 7.7% YTD
   • Read: Organigram Reports A Net Profit In Q1
2. Cronos (CRON): DOWN 8.8% this week; DOWN 9.9% YTD
   • Read: Cronos Group Q3 Financial Report Disappointing: Stock Declines 10%
3. Tilray (TLRY): DOWN 11.3% this week; UP 6.4% YTD
   • Read: Tilray Brands: Q2 Financial Metrics All Declined
4. Aurora (ACB): DOWN 14.2% this week; UP 2.2% YTD
   • Read: Aurora Q2 Financials: Net Revenue +25%, Net Profit -30%, Adj. EBITDA Turned Positive
5. Canopy Growth (CGC): DOWN 21.9% this week; UP 0.4% YTD
   • Read: Canopy Q3: Revenue -14%, Net Loss +15%; To Cut Jobs By ~60%

The release of the dismal financial report from Canopy Growth this week resulted in its stock price crumbling, contributing to the munKNEE Canadian Cannabis LPs Index going DOWN 13.9% this week and it is now only UP 0.1% YTD. Our munKNEE American Cannabis MSO Stocks Index, in comparison, only went DOWN 2.7% this week, and is now DOWN 0.8% YTD.

---

More By This Author:

Canopy Q3: Revenue -14%, Net Loss +15%; To Cut Jobs By ~60%
Aurora Q2 Financials: Net Revenue +25%, Net Profit -30%, Adj. EBITDA Turned Positive
Another BriaCell Therapeutics Goal: A Better Treatment For Prostate Cancer